Clinical Trial Detail

NCT ID NCT02402712
Title Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

Her2-receptor positive breast cancer

Therapies

Docetaxel + Pertuzumab + Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST